Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Levin

Showing results (431-440 of 461) with videos related to

Pageof 47
Sort By:
Journal of Medicinal Chemistry|November 30, 2004
Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitorsAranapakam M Venkatesan, Jamie M Davis, George T Grosu, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 2002
Benzodiazepine inhibitors of the MMPs and TACEFrances C Nelson, Efren Delos Santos, Jeremy I Levin, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|February 24, 2001
[Migraine: dynamics of psychophysiologic pattern]A M Veĭn, A B Danilov, O A Kolosova, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 5, 2004
A novel epilepsy mutation in the sodium channel SCN1A identifies a cytoplasmic domain for beta subunit interactionJ Spampanato, J A Kearney, G de Haan, et al.
Bioorganic & Medicinal Chemistry Letters|September 13, 2005
Synthesis and SAR of highly selective MMP-13 inhibitorsJianchang Li, Thomas S Rush, Wei Li, et al.
Bioorganic & Medicinal Chemistry Letters|October 30, 2009
Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitorsDan M Berger, Nancy Torres, Minu Dutia, et al.
Bioorganic & Medicinal Chemistry|October 12, 2005
Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritisYonghan Hu, Jason S Xiang, Martin J DiGrandi, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2002
Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' groupJ I Levin, J M Chen, M T Du, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2011
Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activityChristoph W Zapf, Jonathan D Bloom, Jamie L McBean, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinasesJ I Levin, Y Gu, F C Nelson, et al.
Pageof 47

Showing results (431-440 of 461) with videos related to

Sort By:
Pageof 47
Journal of Medicinal Chemistry|November 30, 2004
Synthesis and structure-activity relationships of 4-alkynyloxy phenyl sulfanyl, sulfinyl, and sulfonyl alkyl hydroxamates as tumor necrosis factor-alpha converting enzyme and matrix metalloproteinase inhibitorsAranapakam M Venkatesan, Jamie M Davis, George T Grosu, et al.
Bioorganic & Medicinal Chemistry Letters|September 25, 2002
Benzodiazepine inhibitors of the MMPs and TACEFrances C Nelson, Efren Delos Santos, Jeremy I Levin, et al.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova|February 24, 2001
[Migraine: dynamics of psychophysiologic pattern]A M Veĭn, A B Danilov, O A Kolosova, et al.
The Journal of Neuroscience : the Official Journal of the Society for Neuroscience|November 5, 2004
A novel epilepsy mutation in the sodium channel SCN1A identifies a cytoplasmic domain for beta subunit interactionJ Spampanato, J A Kearney, G de Haan, et al.
Bioorganic & Medicinal Chemistry Letters|September 13, 2005
Synthesis and SAR of highly selective MMP-13 inhibitorsJianchang Li, Thomas S Rush, Wei Li, et al.
Bioorganic & Medicinal Chemistry Letters|October 30, 2009
Non-hinge-binding pyrazolo[1,5-a]pyrimidines as potent B-Raf kinase inhibitorsDan M Berger, Nancy Torres, Minu Dutia, et al.
Bioorganic & Medicinal Chemistry|October 12, 2005
Potent, selective, and orally bioavailable matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritisYonghan Hu, Jason S Xiang, Martin J DiGrandi, et al.
Bioorganic & Medicinal Chemistry Letters|April 6, 2002
Anthranilate sulfonamide hydroxamate TACE inhibitors. Part 2: SAR of the acetylenic P1' groupJ I Levin, J M Chen, M T Du, et al.
Bioorganic & Medicinal Chemistry Letters|March 23, 2011
Design and SAR of macrocyclic Hsp90 inhibitors with increased metabolic stability and potent cell-proliferation activityChristoph W Zapf, Jonathan D Bloom, Jamie L McBean, et al.
Bioorganic & Medicinal Chemistry Letters|February 24, 2001
Heteroaryl and cycloalkyl sulfonamide hydroxamic acid inhibitors of matrix metalloproteinasesJ I Levin, Y Gu, F C Nelson, et al.
Pageof 47